TABLE 4.

Results for ⁶⁸Ga-DOTATATE

			Vaccinated (13 patients)		DS (3 patients)
Parameter	Total (14 patients)	Control group (1 patients)	Once (2 patients)	Twice (11 patients)	Once (1 patients)	Twice (2 patients)	Index (%)
Mean interval from vaccination to PET/CT (d)	NA	NA	6 (range, 3–8)	14 (range, 2–21)	3	4 (range, 2–5)	NA
Lymphadenopathy
Patients (n)	12 (86%)	0	2 (15%)	10 (77%)	1 (33%)	2 (67%)	S, 87.5; Sp, 100; PPV, 100; NPV, 50^‡
LN appearance
Benign	12 (100%)	N/A	2 (100%)	10 (100%)	3 (100%)^†
Malignant	0	N/A	0	0	0^†
Equivocal	0	N/A	0	0	0^†
Size (cm) in short axis	0.5–1.1	N/A	0.5–1.1^†		0.5–0.9^†
SUV_max	1–3.5	N/A	1–3.5^†		1.6–3.5^†
Arm (patients [n])	3 (21%)	0	3 (23%)^†		3 (100%)^†		NA
			1 (33%)	2 (67%)	1 (33%)	2 (67%)
DS (patients [n])	3 (21%)	0	3 (23%)^†		—^†		S, 75; Sp, 100; PPV, 100; NPV, 50
			1 (33%)	2 (67%)	—^†

*For unilateral axillary lymphadenopathy only, with increased uptake (SUV_max > 1.0) and benign appearance.
↵^†Applies to both once-vaccinated and twice-vaccinated patients.
↵^‡Control group, only 1 patient.
S = sensitivity; Sp = specificity; NA = not applicable.